Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study

Currently, there are two antifibrotics used to treat idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. Antifibrotics slow disease progression by reducing the annual decline of forced vital capacity (FVC), which possibly improves outcomes in IPF patients. During treatment, patients occ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC pulmonary medicine 2021-07, Vol.21 (1), p.221-13, Article 221
Hauptverfasser:	Suzuki, Yuzo, Mori, Kazutaka, Aono, Yuya, Kono, Masato, Hasegawa, Hirotsugu, Yokomura, Koshi, Naoi, Hyogo, Hozumi, Hironao, Karayama, Masato, Furuhashi, Kazuki, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Nakamura, Yutaro, Inui, Naoki, Nakamura, Hidenori, Suda, Takafumi
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antifibrotic therapy Cohort analysis Disease Disease Progression Drug Administration Schedule Drug Substitution Drug therapy Female Fibrosis Gastrointestinal diseases Humans Idiopathic pulmonary fibrosis Idiopathic Pulmonary Fibrosis - drug therapy Indoles - therapeutic use Japan Lung diseases Male Medical prognosis Patients Prognosis Propensity Score Pulmonary fibrosis Pulmonology Pyridones - therapeutic use Regression analysis Retrospective Studies Software Survival Switch of antifibrotics Treatment Outcome Values Vital Capacity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!